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Abstract
Introduction. Lipid peroxidation (LPO) results from oxidative damage to membrane lipids. Whereas LPO rises in normal 
pregnancy, the effect of gestational diabetes mellitus (GDM) on this process has not been clearly defined.   
Materials and Method. Fasting blood concentrations of malondialdehyde+4-hydroxyalkenals (MDA+4-HDA), as LPO index, 
TNFa soluble receptors (sTNF-R1 and sTNF-R2), and soluble adhesion molecules (sICAM-1, sVCAM-1), were measured in 51 
women at 28 weeks of gestation. The women were divided according to the results of 50.0 g glucose challenge test (GCT) 
and 75.0 g oral glucose tolerance test (OGTT): Controls (n=20), normal responses to both GCT and OGTT; Intermediate Group 
(IG) (n=15), abnormal GCT but normal OGTT; GDM group (n=16), abnormal both GCT and OGTT.   
Results. Glucose concentrations in women diagnosed with GDM were within the range of impaired glucose tolerance. 
There were no significant differences in concentrations of either TNFa soluble receptors R1 and R2, or sICAM-1 or sVCAM-1. 
LPO concentrations [MDA+4-HDA (nmol/mg protein)] were significantly higher in women with GDM than in the other two 
groups [64.1±24.3 (mean±SD), 39.3±23.1, 47.0±18.1, for GDM, IG and Controls, respectively; p<0.05]. In multivariate analysis, 
the only significant independent correlation was between LPO level and glucose at 120 minutes of OGTT (rs=0.42; p=0.009).  
Conclusions. Oxidative damage to membrane lipids is increased in GDM and might result directly from hyperglycaemia. 
Physiological significance of this phenomenon remains to be elucidated.
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INTRODUCTION
Under physiological conditions, biological cells produce 
low or moderate amounts of reactive oxygen species (ROS) 
that are required for life processes. In basal conditions, 
ROS are continuously detoxified by antioxidant systems 
and, therefore, they are not toxic [1]. Overproduction of 
ROS, free radicals included, results in enhanced oxidative 
stress and may lead to several diseases [2]. Alternatively, 
pathological processes in organs or tissues may, in turn, lead 
to an increased formation of ROS and, in consequence, to 
increased damage to macromolecules, such as membrane 
lipids [2, 3]. Oxidative damage to membrane lipids results 
in lipid peroxidation (LPO). The placenta is a major source 
of oxidative stress during pregnancy. As placenta is rich in 
polyunsaturated fatty acids which are highly susceptible 
to attack by ROS, then increased LPO is expected during 
pregnancy, and that assumption has been already clinically 
proven [4].
In normal pregnancy, LPO rises until the middle of the 
2nd trimester and generally returns to normal non-pregnant 
levels in early postpartum [5]. However, the concentrations 
of LPO products and their relationship with insulin 
resistance (IR) indices has not been validated in gestational 
diabetes mellitus (GDM), i.e., a condition characterized 
by hyperglycaemia and increased IR [6]. Pregnancy per se 
constitutes a pro-inflammatory condition associated with an 
inflammatory response characterized by leukocyte activation 
[7], while overproduction of LPO products might occur at 
sites of chronic inflammation [8]. Furthermore, endothelial 
dysfunction, IR and low-degree pro-inflammatory state are 
also features of GDM [9, 10].
Secretory products from adipocytes contribute to 
deterioration in glycaemic control and increased IR, with 
complications, such as type 2 diabetes and atherosclerosis 
[11]. Tumour necrosis factor alpha (TNFa) is implicated in 
the pathogenesis of complications of metabolic syndrome, 
including IR and post-ischemic myocardial dysfunction 
[12, 13]. After binding to its receptors, a proteolytic cleavage 
of the extracellular parts elicits the soluble forms of TNFa 
receptors, named sTNF-R1 (60 kDa) and sTNF-R2 (80 kDa) 
[14]. This process is known as shedding. The concentration 
of these soluble TNFa receptors (sTNFaRs) is proportional 
to previous TNFa action. In fact, sTNFaRs remain elevated 
in plasma for longer periods of time after the administration 
of TNFa and are thought to be a surrogate of previous TNFa 
effects [15, 16]. This is because the two soluble receptor 
forms – sTNF-R1 and sTNF-R2 – have longer half-lives 
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than TNFa, and their concentration may reflect TNFa 
activity [17]. Furthermore, recent evidence suggests that the 
TNFa system and serum sTNF-R1 and sTNF-R2 might be 
associated with the rate of glucose and lipid oxidation during 
hyperinsulinemia in an opposite manner to adiponectin 
[18]. While serum TNFa concentrations were reported 
to be raised in GDM, in most [19, 20, 21, 22], though not 
in all studies [23], there are few data on concentrations of 
TNFa soluble receptors in women with GDM. Binding of 
monocytic cells to vascular endothelium, one of the earliest 
detectable events in atheroslerotic lesion development and 
in inflammatory processes, arises under the influence of 
adhesion molecules, such as soluble intercellular adhesion 
molecule-1 (sICAM-1) and soluble vascular cell adhesion 
molecule-1 (sVCAM-1) [24]. It has been shown that diabetic 
patients have an increase of soluble adhesion molecules 
(sICAM-1, sICAM-2, sVCAM-1, sE-selectin, sL-selectin, sP-
selectin) considered an integral part of the inflammatory 
state [25]. Cellular forms of adhesion molecules mediate 
specific steps of leukocyte-endothelial cell interaction and 
have been implicated in the pathophysiology of pre-clampsia, 
endothelial dysfunction [26], as well as IR [25, 27].
Objective. The presented study aimed to test the hypothesis 
that concentrations of LPO products might be altered in 
GDM. A further aim was to assess any potential relationships 
between LPO products and IR indices and the components 
of TNFa system (i.e., TNFa soluble receptors R1 and R2), 
as well as soluble forms of adhesion molecules (sICAM-1 
and sVCAM-1).
MATERIALS AND METHOD
This was a cross-sectional study performed at 28 weeks 
of gestation. The study group comprised 51 women who 
attended either Obstetric Clinics at the Royal Free Hospital 
in London, UK, or The Department of Endocrinology and 
Metabolic Diseases at The Polish Mother’s Memorial Hospital 
Research Institute in Łódż, Poland, and were screened for 
GDM and evaluated with 50.0 g glucose challenge test (GCT) 
and 75.0 g oral glucose tolerance test (OGTT). Women with 
plasma glucose <7.8 mmol/l one hour after the GCT were 
regarded normal and subjected to routine antenatal care. 
GDM was diagnosed according to the WHO criteria [28]. 
The women were divided into three groups according to 
the results of GCT and OGTT: Controls (n=20) had normal 
responses to GCT and OGTT, Intermediate Group (IG) 
(n=15) had false positive GCT but normal OGTT, while the 
GDM group (n=16) had abnormal both GCT and OGTT. 
Demographic characteristics of study subjects are presented 
in Table 1. The study was approved by the Ethics Committees 
of The Royal Free Hospital in London, UK, and The Polish 
Mother’s Memorial Hospital Research Institute in Łódż, 
Poland.
Measurements. The concentrations of malondialdehyde + 
4-hydroxyalkenals (MDA + 4-HDA), as an index of LPO, 
were measured in serum using the LPO-586 kit purchased 
from Calbiochem (La Jolla, CA, USA). The serum (200 ml) 
was mixed with 650 ml of a methanol: acetonitrile (1: 3, 
v/v) solution, containing a chromogenic reagent, N-methyl-
2-phenylindole and vortexed. After adding 150 ml of 
methanesulphonic acid (15.4 M), the incubation was carried 
out at 45 °C for 40 min. The reaction between MDA + 4-HDA 
and N-methyl-2-phenylindole yields a chromophore, which 
is spectrophotometrically measured at the absorbance of 
586 nm, using a solution of 4-hydroxynonenal (10 mM) as 
the standard. The level of LPO was expressed as the amount 
of MDA + 4-HDA (nmol) per 1 ml of serum.
Having obtained ethical approval, glucose and insulin 
concentrations were measured at 0 minutes, and later at every 
30 minutes, up to 120 minutes of OGTT. IR was assessed by 
HOMA [29] [where HOMA=fasting insulin (μU/ml) × fasting 
glucose (mmol/l)/22.5] and by the insulin resistance index 
(IRI) [30] based on glycaemia and insulinaemia during 
OGTT. The product of the glucose area under the plasma 
glucose curve and insulin area under plasma glucose curve 
is used as an index of IR. TNFa soluble receptors (sTNF-R1 
and sTNF-R2), soluble intercellular adhesion molecule-1 
(sICAM-1) and soluble vascular cell adhesion molecule-1 
(sVCAM-1) were measured by commercial Quantakine Elisa 
assays (R and D systems), intra and inter-assay variation: 
3.6%, 4.4%, 4.6 %, 3.5 % inter-assay variation 3.7, 3.2, 7.4%, 
7.7%, for TNF alpha R1 and R2, and for sICAM-1 and 
sVCAM-1, respectively.
Statistical analysis. The data were analyzed by means of 
simple descriptive statistics and non-parametric tests of 
significance (since not all variables have normal distribution) 
– Mann-Whitney’s U test for comparison of distributions in 
two independent groups, and the Kruskal-Wallis test in the 
case of more than two groups. Associations between LPO and 
other covariates of interest (demographic and clinical) were 
qualified by means of Pearson or Spearman rank correlations. 
In all the analyses, statistical significance was considered 
for p ≤ 0.05. All the calculations were derived by means of 
Statistica v8.0 software.
RESULTS
There were no significant differences between the subgroups, 
regarding age and BMI, both before and during pregnancy 
(Tab. 1). According to the results of the OGTT, the principal 
differences between women with GDM and controls 
pertained to glucose levels after 120 minutes of OGTT 
(Fig. 1), while fasting glucose levels (albeit still higher than 
in controls, p≤ 0.01) were still within the reference range for 
all but one woman with GDM. In women with GDM, glucose 
levels at 120 minutes of OGTT were in the range between 
8.0 mmol/l – 11.6 mmol/l, with only one subject exceeding 
glucose concentration of 11.1 mmol/l (i.e. the cut-off point 
between impaired glucose tolerance and diabetes mellitus 
in non-pregnant subjects). Worsening of glucose tolerance 
was characterised by an increase in fasting glucose in the 
GDM group, and fasting insulin and HOMA index in both 
Table 1. Demographic characteristics (mean ± SD) of subjects 
participating in the study
Parameter GDM  (n=16) IG (n=15) CTRs (n=20) p-value
Age [years] 32.6 ± 4.2 33.0 ± 4.3 31.9 ± 3.7 0.65
BMI before pregnancy [kg/m2] 23.7 ± 3.2 23.5 ± 4.8 23.2 ± 4.2 0.54
BMI current [kg/m2] 27.7 ± 3.6 26.8 ± 4.2 26.4 ± 4.2 0.34
P – value of the Kruskal-Wallis’ test for comparison of distributions between three groups
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Intermediate (i.e., in patients with FPGCT) and in the GDM 
groups in comparison to Controls (p<0.01). However, there 
were no differences in fasting insulin, fasting glucose and 
HOMA index between the Intermediate and GDM groups 
(p>0.10 (Tab. 2). In contrast, there was no difference in the 
estimates of insulin resistance assessed by IRI between the 
Controls and Intermediate groups (0.68±0.25 vs. 0.93±0.29, 
p=0.23). There was, however, a marked difference in the value 
of IRI between the GDM and Intermediate groups (1.67±0.39 
vs. 0.93±0.29, p=0.015), and between the GDM group and 
Controls (p<0.001).
Descriptive statistics for LPO concentrations [MDA+4-
HDA (nmol/mg protein)] are presented in Table 2 and 
Figure 2. LPO concentrations were significantly higher in 
women with GDM than in the other two groups (p<0.05), 
but there were no differences in LPO concentrations between 
Controls vs. Intermediates. Concentrations of other measured 
parameters are also presented in Table 2. There were no 
Table 2. Descriptive statistics of assessed variables for three groups of women: GDM Intermediate (IG) and Controls (CTRs). P-value of the Kruskal-
Wallis’ test for comparison of distributions of these characteristics in three independent groups. Significant differences 
Variable Group n Mean ± SD Inter quart.  r. Min Max  p-value
Glucose 0 min.
[mmo/l]
GDM 16 4.6 ± 1.0 (4.2 ; 4.6) 3.6 8.0 ↑ **CTRs
0.030 IG 15 4.2 ± 0.3 (3.9 ; 4.4) 3.7 4.7
CTRs 20 4.1 ± 0.4 (3.9 ; 4.3) 3.6 4.9
Glucose  120 min. 
[mmo/l]
GDM 16 9.5 ± 1.2 (8.3 ; 10.6) 8.0 11.6 ↑ ***CTRs,  IG
<0.0001 IG 15 6.4 ± 1.0 (5.3 ; 7.3) 4.4 7.6
CTRs 20 5.7 ± 1.2 (4.6 ; 6.6) 3.7 7.7
Insulin 0 min.
 [mU/ml]
GDM 16 10.2 ± 4.1 (7.7 ; 13.2) 3.8 19.9 ↑ ***CTRs
0.0012 IG 15 10.6 ± 6.6  (6.0 ; 13.6) 4.2 27.2 ↑ **CTRs
CTRs 20 6.1 ± 3.9 (3.8 ; 6.5) 2.4 19.7
Insulin  120 min.
 [mU/ml]
GDM 16 120.0 ± 70.4 (75.8 ; 145.1) 52.2 303.4 ↑ ***CTRs
0.0003 IG 15 80.9 ± 43.6 (54.5 ; 105.9) 17.7 180.3 ↑ *CTRs
CTRs 20 50.6 ± 23.1 (35.0 ; 72.8) 15.9 94.4
HOMA
 [mU/ml · mmol/l]
GDM 16 2.22 ± 1.46 (1.46 ; 2.62) 0.61 7.07 ↑ ***CTRs
0.0014 IG 15 2.05 ± 1.36 (1.08 ; 2.84) 0.73 5.32 ↑ **CTRS
CTRs 20 1.15 ± 0.82 (0.67 ; 1.19) 0.38 4.11
IRI
GDM 16 1,50 ± 0.38 (1.02 ; 1.82) 0.91 1.97 ↑ ***CTRs, IG
<0.0001 IG 15 0.93 ± 0.29 (0.81 ; 1.12) 0.31 1.38 ↑ *CTRs
CTRs 20 0.68 ± 0.25 (0.52 ; 0.92) 0.30 1.10
sICAM1
[ng/ml]
GDM 16 364 ± 135 (291 ; 440) 136 606
0.21 IG 15 312 ±  68 (262 ; 372) 202 438
CTRs 20 306 ±  94 (243 ; 344) 192 580
sVCAM1 
[ng/ml]
GDM 16 902 ± 267 (752 ; 1164) 608 2390
0.11 IG 15 1066 ± 387 (878 ; 1274) 320 1826
CTRs 20 1048 ± 374 (842 ; 1169) 578 1516
LPO [MDA+4-HDA (nmol/mg protein)]
GDM 16 64.1 ± 24.3 (44.0 ; 85.9) 36.2 102.3 ↑ * CTRs, IG
0.033 IG 15 39.3 ± 23.1 (17.0 ; 60.8) 11.6 77.5
CTRs 16 47.0 ± 18.1 (34.1 ; 59.0) 23.0 79.0
TNF-RI 
[pg/ml]
GDM 16 1293 ± 456 (1027 ; 1387) 884 2568
0.64 IG 15 1271 ± 312 (1018 ; 1432) 824 1906
CTRs 20 1307 ± 336 (1110 ; 1414) 945 2246
TNF-RII 
[pg/ml]
GDM 16 3478 ± 734 (2903 ; 4023) 2348 4857
0.14 IG 15 3961 ± 693 (3420 ; 4700) 2576 4892
CTRs 20 3959 ± 1041 (3393 ; 4061) 2924 7532
↑ or ↓) between two compared groups, assessed by means of Mann-Whitney’s U test, are indicated by an asterisk: *(p ≤ 0.05); **( p ≤ 0.05); ***(p≤ 0.001) 
Figure 1. Glucose levels in glucose tolerance test (OGTT) in three groups of women: 
Gestational (GDM), Intermediate (IG) and Controls (CTRs). Vertical bars represent 
95% confidence intervals for OGTT levels at different time points. Significant 
differences between groups, assessed by means of Mann-Whitney’s U test, are 
indicated by asterisks: *(p ≤ 0.05); ***(p≤ 0.001)
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significant differences in concentrations of TNFa soluble 
receptors (sTNF-R1 and sTNF-R2), or IL-6, sICAM-1 and 
sVCAM-1 between the groups.
There was a significant correlation between concentrations 
of LPO products and glucose levels at 120 minutes of OGTT 
(r  =  0.45; p  =  0.005) (Fig. 3), but there was no significant 
correlation between LPO levels and age or BMI, or 
concentrations of other measured parameters. Glucose levels 
correlated with insulin levels (r = 0.35; p = 0.014), however, in 
the multivariate model of regression, with concentrations of 
insulin and glucose at 120 min as covariates, glucose was the 
only significant independent variable with partial correlation 
coefficient rp = 0.52 (p = 0.0012).
DISCUSSION
The main finding of the presented study was to demonstrate 
increased concentrations of LPO products in women with 
GDM in comparison to healthy pregnant controls, as well as 
with pregnant women with less pronounced abnormalities 
of glucose tolerance (i.e., false positive glucose challenge test, 
but normal results of 75.0 g OGTT). The main difference 
between women with GDM and those from the Control and 
Intermediate groups pertained predominantly to glucose 
levels at 120 minutes of OGTT (Fig. 1), while those from the 
Intermediate group were more insulin-resistant than controls 
(HOMA: 2.05±1.36 vs. 1.15±0.82, p<0.01).
As concentrations of LPO products did not correlate 
with the indices of insulin resistance (HOMA, IRI), but 
correlated independently with glucose concentration at 
120 minutes of OGTT, then it is likely that glycaemia, rather 
than insulinaemia, might be the driving force behind raised 
concentrations of LPO products in women with GDM.
As mentioned above, in normal pregnancy LPO rises until 
the middle of the second trimester and generally return to 
non-pregnant levels in early postpartum [4, 5]; however, 
there are very scanty data for LPO levels in GDM. Dey 
et al. [31] reported a significant increase in the erythrocytic 
glutathione, serum total glutathione and protein thiols in 
GDM maternal blood when compared to controls, whereas 
erythrocytic superoxide dismutase exhibited a marked 
decrease in GDM. The authors, however, did not attempt 
to correlate LPO concentrations with glucose or insulin 
resistance indices, although they postulated that elevated 
glucose levels might induce oxidative stress in GDM mothers. 
Also, Karacay et al. [32] reported raised myeloperoxidase 
(MPO) in 27 women with GDM in comparison to 27 women 
with pre-clampsia and 29 controls, suggestive of raised LPO 
in GDM. These patients were tested for GDM at a later stage 
of pregnancy (up to 36 weeks). Again, however, there were no 
data on correlation with glucose, insulin, insulin resistance 
indices, as well as other parameters. Indeed, to the best of 
our knowledge, this is the first study, where concentrations 
of LPO products were tested for direct relationship with 
glucose and insulin resistance indices in pregnant women 
across the whole range of abnormalities of glucose intolerance 
(including those with false positive 50.0 g Glucose Challenge 
Test, i.e., our Intermediate group), as well as concentrations 
of soluble forms of adhesion molecules (sICAM-1 and 
sVCAM-1) and soluble TNFa receptors R1 and R2.
There are experimental data suggesting that glucose 
induces lipid peroxidation and inactivation of membrane-
associated ion-transport enzymes in human erythrocytes 
in vivo and in vitro [33], although at concentrations higher 
than those observed in patients with GDM in the presented 
study. These data were later confirmed by other authors; for 
instance, Ahmed et al. [34] suggested that elevated levels of 
glucose induced oxidative stress that is ultimately reflected by 
the increased malondialdehyde (MDA) levels in erythrocyte 
membranes of diabetic patients. The authors also suggested 
that elevated concentrations of antioxidant enzymes may be 
considered as markers for vascular injury in patients with 
type 2 diabetes. Hyperglycaemia also induced an increase 
in antioxidant enzymes and a relationship seems to exist 
between diabetic complications and elevated levels of these 
enzymes.
There is also some evidence that oxidative stress may be 
involved in the progression and/or pathogenesis of GDM, 
as the release of 8-isoprostane (a marker of oxidative stress) 
was greater from placentas, subcutaneous adipose tissue, 
and skeletal muscles of women with GDM, in contrast 
to healthy pregnant controls [35]. Interestingly, elevated 
activity of butyrylcholinesterase, i.e. an enzyme involved 
in the reduction of oxidative stress, was also reported to be 
elevated in serum and placenta in gestational diabetes and in 
pregnant women with type 2 diabetes on insulin vs. women 
with diet-controlled GDM [36].
Figure 2. Box and whiskers plot for levels of LPO [MDA+4-HDA(nmol/mg protein)] 
in three groups of women: Gestational (GDM), Intermediate (IG) and Controls (CTRs). 
Significant differences between groups, assessed by means of Mann-Whitney’s U 
test, are indicated by an asterisk: *(p ≤ 0.05). LPO concentrations were significantly 
higher in comparison to both Controls and Intermediate groups.
Figure 3. Correlation between LPO concentrations and glucose levels at 120 
minutes of 75.0 g OGTT (r= 0.45, p = 0.005).
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In contrast, data on the relationship between LPO and 
insulin resistance indices are less clear. For example, Facchini 
et al. [37] demonstrated a positive correlation between plasma 
lipid hydroperoxide concentrations and insulin resistance 
measured by the steady-state plasma insulin (SSPI) and 
glucose (SSPG) concentrations in response to a 180-min 
constant infusion of octreotide (r=0.42, p=0.01), but there was 
no correlation between HOMA and malondialdehyde (MDA) 
concentrations in women with impaired glucose tolerance 
[38], i.e., within the range of glucose concentrations similar to 
those observed in the presented study. It should also be noted 
that although LPO concentrations were reported to be raised 
in women with pre-clampsia [39], none of the women in the 
current study had any clinical features of pre-eclampsia at the 
time of testing, while pre-eclampsia subsequently developed 
in only one subject with GDM; therefore, the development 
of subsequent pre-eclampsia was unlikely to explain the 
elevated LPO concentrations in women with GDM.
Interestingly, the presented study failed to demonstrate 
differences in serum concentrations of TNFa soluble 
receptors in women with GDM vs. controls. This is in keeping 
with the results of Kinalski et al. [19, 40], but in contrast 
to the results of Winkler et al. [41] who reported higher 
serum concentrations of TNFa soluble receptors R1 and 
R2 in women with GDM. It must be appreciated, however, 
that regulation of the TNFa system in pregnancy is very 
complex, and that serum concentrations of TNFa soluble 
receptors reflect the contribution of various organs (including 
placenta) into the systemic circulation. Namely, components 
of the TNFa system may be released from placenta, adipose 
tissue, neutrophils and other sources [42]. There are data that 
in response to oxidative stress, GDM placenta releases less 
TNFa, in turn though, the GDM placenta is characterised 
by increased antioxidant gene expression, yet it appears to 
be less responsive to exogenous oxidative stress than tissues 
obtained from normal pregnant women [42]. On the other 
hand, high glucose concentrations induce TNFa release from 
the placenta and adipose tissue in women with GDM [43]. In 
such circumstances, the net release of TNFa and its soluble 
receptors from placenta may, at least in theory, depend on 
the balance between the severity of an exogenous oxidative 
stress and the degree of hyperglycaemia.
In summary, the presented study has demonstrated 
increased concentrations of LPO products in women with 
GDM, despite a relatively mild degree of glucose intolerance 
(if not pregnant, all but one subjects would be classified 
as impaired glucose tolerance only). Furthermore, the 
independent positive correlation with glucose levels at 120 
minutes of OGTT suggests that the increased oxidative 
damage to lipids might result directly from hyperglycaemia. 
This hypothesis, however, still remains to be clinically and 
experimentally proven. The fact that the study failed to 
observe the expected differences in concentrations of other 
parameters (TNFa soluble receptors R1 and R2, sICAM-1, 
sVCAM-1) implies that an increase in lipid peroxidation 
might be a relatively early phenomenon in women with 
GDM, potentially antedating the change of concentrations 
of certain adipokines or inflammatory markers.
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